4th RNAi- Based Therapeutics Summit

Memo

Welcome to the 4rd Annual RNAi - Based Therapeutics Summit: Unleash the Potential of siRNA Therapies in Extrahepatic Tissues Bringing together both technical and strategic expertise sharing case studies with actionable insights, the 4th RNAi-Based Therapeutics Summit returns to Boston to address the most pressing challenges preventing the widespread adoption of RNAi therapies and tackling targets beyond the liver. With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia, join us to discuss novel delivery modalities, next-generation chemistries, clinical updates, scaling up. and more. URLs:Tickets: https://go.evvnt.com/1424501-2?pid=5569 Brochure: https://go.evvnt.com/1424501-3?pid=5569  Date and Time: On Tue, 21 Mar 2023 08:00 - Thu, 23 Mar 2023 19:00 Venue details: Hilton Boston Logan Airport, One Hotel Dr, Boston, Massachusetts, 02128, United States Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): USD 4946.00,Drug Developer Pricing - Conference Only: USD 2999.00,Academic and Research Institute Pricing - 3 Day Pass (Conference + Workshop Day): USD 4246.00,Academic and Research Institute Pricing - Conference Only: USD 2599.00,Standard Pricing - 3 Day Pass (Conference + Workshop Day): USD 5846.00,Standard Pricing - Conference Only: USD 3599.00 Speakers: Iris Grossman, Chief therapeutics officer, Eleven Therapeutics, Richard Welch, Vice President - Chemistry, Manufacturing and Controls, Sirnao, Debasis Patra, VP CMC, OliX US, Qi Tang, Postdoctoral Fellow, University of Massachusetts Medical School, Quintin Wills, CSO and Co-Founder, Ochre Bio Ltd., Nagy Habib, Head of R and D, MiNA Therapeutics, Brad Niles, CEO, ARIZ, Ali Shah, Co-Founder and Chief Executive Officer, Tallas Biotech, Ines de Santiago, Senior Principal Biologist, e-Therapeutics PLC, Anja Hog, Chief Development Officer, Heqet Therapeutics, Seungil Ro, Professor/President, University of Nevada, Reno School of Medicine/RosVivo Therapeutics, Dong-ki Lee, CEO, OliX Pharmaceuticals, Guangnong (Sunny) Zhang, Associate Director, Dicerna TRU of Novo Nordisk, Michael Khan, Chief Executive Officer, ARGONAUTE RNA Ltd., David Evans, Chief Scientific Officer, Sirnaomics, Alan Horsager, President and CEO, Duet Biotherapeutics, Samuel Wickline, Chief Scientific Officer, Altamira Therapeutics, June Park, CEO, siRNAgen Therapeutics, Sean Bedingfield, Advisor - Genetic Medicine, Eli Lilly and Co., Julia Alterman, Assistant Professor, University of Massachusetts Medical School, Yao Xin, Principal Investigator, Aro Biotherapeutics